1.We registered Lanzhou Royacel Biotechnology Co., Ltd.
2.The Royacel trademark was registered by our team.
3.We started our business since 1996, providing the animal vaccine market with primary or sterilized serum.

2004

1.We started to comprehensively test our serum on cells.
2.The detection of physical and chemical properties, as well as of microbes, were systemically optimized.
3.Our originally invented method of enclosed six-bagged blood collection process was applied in production.

2005

1.We settled at the development zone of Lanzhou.
2.The construction of qualified production workshop and experimental area had completed.
3.The construction of qualified purification workshop at Inner Mongolia had completed.
4.According to GMP concept, we started to build up our management system of production of bovine serum.
5.We achieved ISO 9001 certification of quality.

2006

1.We passed the on-site inspection of Standard Enterprise for the production of bovine serum.
2.Our new born serum was proved to qualify for the roller bottle culture of hamster primary kidney cells.
3.We became the supplier of 福尔 (Beijing) Co., Ltd and Yatai (Jilin) Co., Ltd.

2007

1.The first systematic upgrade of quality management system had completed.
2.We obtained the certification of Standard Enterprise for the production of Bovine Serum.
3.Our new born serum was proved to qualify for the roller bottle culture of bovien primary kidney cells.
4.We became the supplier of Institute of Biological Products (Lanzhou) Co., Ltd.

2008

1.We established the first production and purification workshop of which the material was collected from a cattle ranch.
2.The blood for serum production was collected from cows raised in standardized large-scale grazing land.
3.Our new born serum was proved to qualify for the culture of Vero cells in bioreactor.
4.We became the supplier of Chengda (Liaoning) Biotechnology Co., Ltd.

2009

1.We systematically upgraded the management of production, which includes the on-job assessment of workers, full QA supervision, the uniform purchase and distribution of raw material, stock management and cold chain transportation.
2.We started our research on the origin and quality of cows, blood collection models and coagulation process, and this laid the foundations of the advancement of our production.

2010

1.The regulation of our company was reformed to a more modern and standard model.
2.Our new born serum was proved to qualify for the mass production of diploid cells.
3.We became the supplier of Sinovac (Dalian) Vaccine Technology Co., Ltd.
4.The screening method for the BVDV antibody and antigen was established.

2011

1.We developed the comprehensive evaluation system of bovine serum. This provided us a power tool of method modification and research.
2.We began to applied the concept of biological manufacturing management to fully upgrade our production system.
3.Compared with those basic business models, we manufactured goods with preciseness to ensure the quality and stability of our products.

2012

1.The full test of bovine serum in Pharmacopoeia of the People’s Republic of China was independently completed by us.
2.We became the supplier of Sinovac (Beijing) Vaccine Technology Co., Ltd.
3.We passed the ISO9001 annual audit.
4.We started to developed fetal bovine serum (Product No.: RY-F11) specialized for monoclonal antibody preparation.

2013

1.The second systematic upgrade of quality management system had completed.
2.We had passed the re-qualification of bovine serum manufacturer certificate.
3.The salary grade evaluation system was fully implemented in our company to break boundaries between departments, education, seniority and post.
4.We developed novel business mode making Royacel Biotechnology an open operating platform.

2014

1.Researchers of Microbiology and Immunology joined our team to develop premium Fetal bovine serum (Product No.: RY-F22).
2.By improving the quality control of blood source, we optimized the production of Fetal bovine serum (Product No.: RY-F22), which can now support the cell growth with perfect morphology and a clean background.
3.The comprehensive evaluation of Fetal bovine serum (Product No.: RY-F11) was completed.
4.The office in Beijing was set up.

2015

1.For the first time we included human capital in company assets. We established an innovative benefit distribution model based on valuation.
2.By improving the coagulation process, we optimized the production of Fetal bovine serum (Product No.: RY-F22), which can now formulate optimal medium supporting the stable growth of cells.
3.We established the method detecting residual antibiotics in Bovine Serum.

2016

1. Our Fetal bovine serum (Product No.: RY-F22) was upgraded to achieve a wider applicability.
2. Our high quality Newborn Bovine Serum, which can specifically apply to diploid cells, accomplished system verification.
3.Our high quality Newborn Bovine Serum passed hemoglobin screening criteria by National Medical Products Administration.
4.With our excellent products and reputation, the corporate entered the stage of rapid development. We achieved the annual sale

2017

1.The upgrade of production area and experimental had completed.
2.We were recognized as Hi-tech Enterprise.
3.We improved the downstream production of proteins in Fetal bovine serum (Product No.: RYF22) by controlling the quality and easing the stress response of cows.
4.Our Fetal bovine serum (Product No.: RY-F22) accomplished system verification, and its comprehensive index met international quality standards.

2018

1.The Italian IMA filling line were put into use.
2.The third systematic upgrade of quality management system had completed.
3.We passed the on-site inspection of Standard Enterprise.
4.We were constantly receiving good feedback from users of Fetal bovine serum (Product No.: RY-F22) in research colleges and institutions across the country.
5.Our serum products passed tests on biochemical indices.
6.The office in Shanghai was set up.

2019